
Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC
Ultra-low prostate-specific antigen (PSA) responses were linked with improved clinical outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide (Nubeqa) plus androgen deprivation therapy (ADT), according to …